Recent Updates — HSIC
On September 21, 2026, Henry Schein, Inc. entered into the Fourth Amended and Restated Revolving Credit Agreement, increasing its aggregate revolving credit commitments from $1 billion to $1.25 billion. The amendment extends the termination date to September 19, 2031 and modifies certain financial definitions and covenants. Proceeds will support working capital, general corporate purposes, capital expenditures, stock repurchases, debt refinancing, and potential acquisitions. This is a significant financing update for Henry Schein, Inc., which distributes health care products and provides business management services to dental, medical, and veterinary professionals.
Henry Schein, Inc. reported second quarter 2026 financial results on August 4, 2026, posting GAAP diluted EPS of $0.82 compared to $0.70 in the prior year period. Total net sales reached $3.5 billion, a 6.7% increase from Q2 2025, driven by 4.6% internal growth and favorable foreign currency impacts. The company raised its full-year 2026 guidance, projecting non-GAAP diluted EPS between $5.29 and $5.39, sales growth of 4.5% to 5.5%, and Adjusted EBITDA growth in the mid-to-high-single digits. During the quarter, Henry Schein repurchased approximately 2.6 million shares for $200 million, leaving $455 million authorized for future buybacks. The company operates as a global provider of healthcare solutions, products, and technology platforms to office-based dental and medical practitioners.
Henry Schein, Inc. announced leadership transitions effective October 30, 2026, when Executive Vice President and Chief Operating Officer Michael S. Ettinger, Executive Vice President and Chief Strategic Officer Mark E. Mlotek, and Senior Vice President James Mullins will transition from their current roles into senior advisory positions. The company is simultaneously restructuring its governance by creating the Henry Schein Leadership Team to replace the Executive Management Committee and integrating its global supply chain organization with its distribution group. These executives are entitled to payments under the Company’s Executive Severance Plan. This organizational change aims to simplify the operating model, accelerate decision-making, and enhance customer-centricity within the healthcare products and services industry.
Henry Schein, Inc. announced the results of its 2026 Annual Meeting, which included the election of ten directors and the approval of a shareholder proposal to govern by majority vote. The company also announced the appointment of William K. "Dan" Daniel as the new Independent Chairman of the Board of Directors.
Henry Schein, Inc. issued a press release on May 5, 2026, reporting its financial results for the three months ended March 28, 2026. The filing serves as a formal announcement of these results but does not disclose specific financial figures within the text of the report.